CRBP

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Corbus Pharmaceuticals Holding

NASDAQ | CRBP

11.54

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$208.53M

Market Cap

-

P/E Ratio

-5.49

EPS

$20.56

52 Week High

$4.64

52 Week Low

HEALTHCARE

Sector

CRBP Chart

Recent Chart
Price Action

CRBP Technicals

Tags:

CRBP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$600K
Total Revenue $0
Cost Of Revenue $600K
Costof Goods And Services Sold $600K
Operating Income -$49M
Selling General And Administrative $16M
Research And Development $32M
Operating Expenses $48M
Investment Income Net -
Net Interest Income $4.4M
Interest Income $6.3M
Interest Expense $1.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $600K
Income Before Tax -$40M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$40M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$38M
Net Income -$40M

Revenue & Profitability

Earnings Performance

CRBP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $156M
Total Current Assets $153M
Cash And Cash Equivalents At Carrying Value $17M
Cash And Short Term Investments $17M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $132M
Other Current Assets $3.9M
Other Non Current Assets -
Total Liabilities $13M
Total Current Liabilities $12M
Current Accounts Payable $4.8M
Deferred Revenue -
Current Debt -
Short Term Debt $1.6M
Total Non Current Liabilities $1.6M
Capital Lease Obligations $3.2M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.2M
Other Current Liabilities $5.4M
Other Non Current Liabilities -
Total Shareholder Equity $142M
Treasury Stock -
Retained Earnings -$477M
Common Stock $1K
Common Stock Shares Outstanding $11M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$42M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -$2.7M
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$121M
Cashflow From Financing $167M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$40M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$600K
Total Revenue $0
Cost Of Revenue $600K
Costof Goods And Services Sold $600K
Operating Income -$49M
Selling General And Administrative $16M
Research And Development $32M
Operating Expenses $48M
Investment Income Net -
Net Interest Income $4.4M
Interest Income $6.3M
Interest Expense $1.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $600K
Income Before Tax -$40M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$40M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$38M
Net Income -$40M

CRBP News

CRBP Profile

Corbus Pharmaceuticals Holding Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology firm based in Norwood, Massachusetts, focused on developing groundbreaking therapies that target the endocannabinoid system. With a robust pipeline aimed at treating unmet medical needs in autoimmunity, fibrosis, and oncology, Corbus is well-positioned to transform chronic disease management and improve patient outcomes. Its unique cannabinoid-based treatment approach presents a compelling investment opportunity for institutional investors seeking to capitalize on innovative advancements within the healthcare landscape.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+51.88%
$1.61
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
AMZE
+23.68%
$0.48
TLRY
-22.27%
$0.80
IPG
-1.95%
$24.57
BITF
+10.80%
$3.43
INTC
+9.08%
$40.15
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
TSLA
+1.71%
$426.58
BYND
-4.59%
$0.97
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
KVUE
+1.11%
$17.22
RUBI
-26.31%
$0.15
CLSK
+11.97%
$15.06
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BMNR
+3.76%
$32.93
PLUG
+2.27%
$2.02
BIYA
+10.67%
$0.27
INHD
-0.79%
$0.22
SRM
+53.27%
$10.30
CHR
-2.55%
$0.04
ONMD
+31.69%
$1.87
SNAP
+0.37%
$7.63
WULF
+4.51%
$15.51
TWOH
0.00%
$0.00
BMNU
+3.72%
$7.79
CIFR
+7.41%
$20.56
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AAL
+0.72%
$14.03
MARA
+4.18%
$11.57
VALE
+0.79%
$12.61
ONDS
-4.36%
$7.88
SOFI
+4.31%
$29.72
GPUS
-9.06%
$0.30
NIO
+1.09%
$5.51
F
+0.61%
$13.27
AFMD
-34.94%
$0.18
DEFT
+9.24%
$1.51
BURU
+7.72%
$0.22
APLD
+5.05%
$24.94
BTBT
+1.15%
$2.34
KWM
+17.30%
$0.77
GOOGL
-0.26%
$319.09
SMX
+244.97%
$60.02
AMZN
+1.77%
$233.22
CRCL
+9.28%
$79.38
BTG
+3.25%
$4.61
AIIO
-9.09%
$0.70
GRYP
-10.38%
$1.38
DVLT
-7.05%
$1.97
HBI
-2.20%
$6.44
ACHR
+4.79%
$7.84
MODV
-25.22%
$0.43
BAC
+1.28%
$53.67
AMD
+1.53%
$217.53
IBRX
+9.15%
$2.32
CAN
+10.07%
$1.01
GRAB
+2.34%
$5.44
RIOT
+6.97%
$16.00
IREN
-1.31%
$47.81
AG
+12.47%
$15.19
NGD
+5.92%
$8.30
KDLY
+7.20%
$0.49
DNN
+0.39%
$2.57
VEEE
+50.56%
$2.68
YCBD
-3.44%
$0.53
NVO
+1.21%
$49.30
CRCA
+17.43%
$4.32
AMC
+5.99%
$2.43
TMC
+17.92%
$6.87
GOOG
-0.34%
$319.17
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
RIG
+1.97%
$4.38
PFE
+0.05%
$25.72
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
RIVN
+4.82%
$16.96
ZAPP
-46.30%
$0.15
AGNC
-0.80%
$10.47
CDE
+6.08%
$17.17
SMR
+4.38%
$19.87
SNDK
+3.83%
$223.28
HOOD
+0.22%
$128.49
MSTR
+0.01%
$175.66
WBD
+0.94%
$24.10
BTE
+2.84%
$3.25
ITUB
+2.02%
$7.81
EXK
+15.28%
$9.93
HL
+4.56%
$16.69
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+51.88%
$1.61
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
AMZE
+23.68%
$0.48
TLRY
-22.27%
$0.80
IPG
-1.95%
$24.57
BITF
+10.80%
$3.43
INTC
+9.08%
$40.15
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
TSLA
+1.71%
$426.58
BYND
-4.59%
$0.97
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
KVUE
+1.11%
$17.22
RUBI
-26.31%
$0.15
CLSK
+11.97%
$15.06
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BMNR
+3.76%
$32.93
PLUG
+2.27%
$2.02
BIYA
+10.67%
$0.27
INHD
-0.79%
$0.22
SRM
+53.27%
$10.30
CHR
-2.55%
$0.04
ONMD
+31.69%
$1.87
SNAP
+0.37%
$7.63
WULF
+4.51%
$15.51
TWOH
0.00%
$0.00
BMNU
+3.72%
$7.79
CIFR
+7.41%
$20.56
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AAL
+0.72%
$14.03
MARA
+4.18%
$11.57
VALE
+0.79%
$12.61
ONDS
-4.36%
$7.88
SOFI
+4.31%
$29.72
GPUS
-9.06%
$0.30
NIO
+1.09%
$5.51
F
+0.61%
$13.27
AFMD
-34.94%
$0.18
DEFT
+9.24%
$1.51
BURU
+7.72%
$0.22
APLD
+5.05%
$24.94
BTBT
+1.15%
$2.34
KWM
+17.30%
$0.77
GOOGL
-0.26%
$319.09
SMX
+244.97%
$60.02
AMZN
+1.77%
$233.22
CRCL
+9.28%
$79.38
BTG
+3.25%
$4.61
AIIO
-9.09%
$0.70
GRYP
-10.38%
$1.38
DVLT
-7.05%
$1.97
HBI
-2.20%
$6.44
ACHR
+4.79%
$7.84
MODV
-25.22%
$0.43
BAC
+1.28%
$53.67
AMD
+1.53%
$217.53
IBRX
+9.15%
$2.32
CAN
+10.07%
$1.01
GRAB
+2.34%
$5.44
RIOT
+6.97%
$16.00
IREN
-1.31%
$47.81
AG
+12.47%
$15.19
NGD
+5.92%
$8.30
KDLY
+7.20%
$0.49
DNN
+0.39%
$2.57
VEEE
+50.56%
$2.68
YCBD
-3.44%
$0.53
NVO
+1.21%
$49.30
CRCA
+17.43%
$4.32
AMC
+5.99%
$2.43
TMC
+17.92%
$6.87
GOOG
-0.34%
$319.17
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
RIG
+1.97%
$4.38
PFE
+0.05%
$25.72
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
RIVN
+4.82%
$16.96
ZAPP
-46.30%
$0.15
AGNC
-0.80%
$10.47
CDE
+6.08%
$17.17
SMR
+4.38%
$19.87
SNDK
+3.83%
$223.28
HOOD
+0.22%
$128.49
MSTR
+0.01%
$175.66
WBD
+0.94%
$24.10
BTE
+2.84%
$3.25
ITUB
+2.02%
$7.81
EXK
+15.28%
$9.93
HL
+4.56%
$16.69
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.